This report represents a unique collaborative effort among international specialists in the field of oncology and reproductive medicine. An evidence based approach was used to develop recommendations regarding surveillance for premature ovarian insufficiency in female childhood, adolescent and young adult cancer survivors. In particular, because females exposed to specific gonadotoxic treatments including alkylating agents and ovarian radiation are at highest risk for ovarian insufficiency, these survivors should be monitored closely before and after puberty. The focus of monitoring should be on growth, pubertal development, assessment of menstrual function and measurement of serum FSH and Estradiol. The authors concluded that AMH may be a reasonable adjunct for assessing ovarian reserve in women at least 25 years of age.